A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2016
At a glance
- Drugs Pazopanib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms PAZOTHYR
- 07 Jun 2017 Biomarkers information updated
- 18 Aug 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2017.
- 18 Aug 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2017.